Selinexor clinical trials
Also written KPT-330, Xpovio and ATG-010.
How each study uses selinexor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the selinexor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 3 Jul 2019 · XPOVIO · NDA 212306 (FDA, Drugs@FDA)
- European Union
- 26 Mar 2021 · Nexpovio · EMEA/H/C/005127 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
163 studies that test it; most in 2014 (23)
| Year | Studies |
|---|---|
| 2012 | 2 |
| 2013 | 1 |
| 2014 | 23 |
| 2015 | 21 |
| 2016 | 5 |
| 2017 | 5 |
| 2018 | 7 |
| 2019 | 5 |
| 2020 | 12 |
| 2021 | 20 |
| 2022 | 12 |
| 2023 | 17 |
| 2024 | 13 |
| 2025 | 11 |
| 2026 | 9 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 40 · Other 123
Karyopharm Therapeutics Inc (31) · National Cancer Institute (NCI) (5) · St. Jude Children's Research Hospital (5) · H. Lee Moffitt Cancer Center and Research Institute (5) · University Health Network, Toronto (4) · Antengene Corporation (4) · Memorial Sloan Kettering Cancer Center (4) · Ruijin Hospital (4)
Often tested with
Tested in the same studies.
Dexamethasone (17) · Venetoclax (7) · Lenalidomide (6) · Pomalidomide (6) · Azacitidine (6) · Bortezomib (5) · Carfilzomib (4) · Daratumumab (4)
Related medicines
As reviewed, each with the page that says it.
- One of XPO1 Inhibitor source
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 3 phase 3 studies under way
Selinexor is the comparator. A study of two new drugs counts under both.
- 1Anti-CD3/Anti-BCMA Bispecific Antibody TQB2934 · Chia Tai Tianqing Pharmaceutical Group Co., Ltd. · next primary completion Dec 2028
- 1GPRC5D/BCMA/CD3-targeting T-cell Engager IBI3003 · Innovent Biologics (Suzhou) Co. Ltd. · next primary completion May 2029
- 1Purinostat · Chengdu Zenitar Biomedical Technology Co., Ltd · next primary completion Jun 2029
Reaching primary completion within a year · 19, 2 in phase 3
Studies that test selinexor, phase 3 first.
- Dec 2026A Study of Rituximab-Gemcitabine-Dexamethasone-Platinum (R-GDP) With or Without Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaPhase 2/3 · Karyopharm Therapeutics Inc
- Sep 2027Twice-per-weekSelinexor, 2 Days MelphalanPhase 3 · Institute of Hematology & Blood Diseases Hospital, China
- Nov 2026Selinexor Combined With BEAM for ASCT in R/R DLBCL With MYC PositivePhase 2 · Ruijin Hospital
- Dec 2026Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)Phase 2 · Karyopharm Therapeutics Inc
- Dec 2026"Selinexor+Pegaspargase+Dexamethasone"in Ⅰ/Ⅱ NKTCLPhase 1/2 · Mingzhi Zhang
- Dec 2026Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell LymphomaPhase 2 · Canadian Cancer Trials Group
- Dec 2026HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMPhase 2 · Duke University
- Apr 2027A Trial of Selinexor, Ruxolitinib and MethylprednisolonePhase 1 · Oncotherapeutics
- Apr 2027Selinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia PatientsPhase 2 · Wake Forest University Health Sciences
- May 2027Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialPhase 2 · National Cancer Institute (NCI)
Studies
Open first, then newest update. How each study uses selinexor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 163
- Testing Atezolizumab With Selinexor in People ≥ 12 Years Old With Alveolar Soft Part Sarcoma, AXIOM TrialRecruitingPhase 2National Cancer Institute (NCI)NCT05333458Written as Selinexor
- Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous TreatmentRecruitingPhase 1/2National Cancer Institute (NCI)NCT05432804Written as Selinexor
- A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.RecruitingPhase 2Karyopharm Therapeutics IncNCT04414475Written as Selinexor
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasRecruitingPhase 2John MascarenhasNCT07447817Written as Selinexor
- A Study of Selinexor in People With Wilms Tumors and Other Solid TumorsRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05985161Written as Selinexor
- Selinexor Maintenance Post CAR-T Cell Therapy for Multiple MyelomaRecruitingPhase 1Washington University School of MedicineNCT07200102Written as Selinexor
- Imlunestrant/Abemaciclib/Selinexor in Ovarian and EndometrialNot yet recruitingPhase 2Dana-Farber Cancer InstituteNCT07832227Written as Selinexor
- A Study of Selinexor, in Combination With Carfilzomib, Daratumumab or Pomalidomide in Patients With Multiple MyelomaRecruitingPhase 2Hackensack Meridian HealthNCT04661137Written as Selinexor 60 MG
- HCMT/MM2401: Ph2 Study of Selinexor + Bispecific Antibody for RRMMRecruitingPhase 2Duke UniversityNCT06822972Written as Selinexor 40 mg
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple MyelomaRecruitingPhase 1/2Natalie CallanderNCT07479979Written as Selinexor
- NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS)RecruitingPhase 1/2St. Jude Children's Research HospitalNCT06239272Written as Selinexor
- New Genotype-guided Treatment in Newly Diagnosed PTCLNot yet recruitingPhase 1/2Ruijin HospitalNCT07706959Written as Azacitidine plus Selinexor with CHOP
- Using Tumor Models to Determine TreatmentsRecruitingPhase 2University Health Network, TorontoNCT06813079Written as Selinexor
- The Efficacy and Safety of Selinisole Combined With Azacitidine and Venetoclax in the Treatment of Newly Diagnosed High-risk Myeloid Tumors With TP53 MutationsNot yet recruitingNot applicableBing HanNCT07632170Written as Selinexor
- Selinexor Monotherapy for Cytoreduction in BCR::ABL1-Negative Myeloproliferative NeoplasmsNot yet recruitingPhase 2Zhongshan Hospital (Xiamen), Fudan UniversityNCT07626021Written as Selinexor
- A Study Comparing QLS32015 Monotherapy Versus Pomalidomide, Dexamethasone (Pd) or Selinexor, Dexamethasone (Sd) in Participants With Relapsed or Refractory Multiple MyelomaRecruitingPhase 3Qilu Pharmaceutical Co., Ltd.NCT07138209Written as Selinexor
- A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2Sun Yat-sen UniversityNCT07574528Written as Selinexor
- Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell LymphomaNot yet recruitingPhase 2Beijing Tongren HospitalNCT07554482Written as Selinexor
- Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin LymphomaRecruitingPhase 1/2Samsung Medical CenterNCT06552559Written as Selinexor
- Selinexor, Venetoclax, and Dexamethasone (XVenD) in t(11;14)-Positive Relapsed/Refractory Multiple MyelomaRecruitingPhase 2University of MiamiNCT05530421Written as Selinexor
See all 163 studies that test selinexor →
Given beside what is tested · 11 — selinexor is usual care or a partner of the new treatment
- Selinexor and Backbone Treatments of Multiple Myeloma PatientsRecruitingPhase 1/2Karyopharm Therapeutics IncNCT02343042Written as Selinexor
- Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial)RecruitingPhase 2Sun Yat-sen UniversityNCT06517511Written as Selinexor Oral Tablet [Xpovio]
- Golidocitinib Combined With Selinexor for CAEBVDRecruitingPhase 2/3Beijing Friendship HospitalNCT07369739Written as Selinexor (combination therapy)
- A Clinical Study on the Efficacy and Safety of Methotrexate (MTX) or Thiotepa (for MTX Intolerance) or Temozolomide (TMZ) Combined With Orelabrutinib and Selinexor in Relapsed/Refractory Primary or Secondary Central Nervous System Lymphoma(SELINA)RecruitingNot applicableRuijin HospitalNCT07191431Written as Selinexor+Orelabrutinib+Methotrexate/Thiotepa/Temozolomide
- A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCLRecruitingPhase 1/2Fudan UniversityNCT06966154Written as Selinexor
- Second-line Immunotherapy for ES-SCLCRecruitingNot applicableTianjin Medical University Cancer Institute and HospitalNCT06853678Written as Selinexor
- Selinexor in Combination With Immunomodulator (Thalidomide/Pomalidomide/Lenalidomide)in RRMMRecruitingPhase 2Juan DuNCT04941937Written as Selinexor
- Study of Selinexor in Combination With Backbone Treatments or Novel Therapies In Participants With Relapsed or Refractory (RR) Diffuse Large B-Cell Lymphoma (DLBCL)WithdrawnPhase 1/2Karyopharm Therapeutics IncNCT04607772Written as Selinexor
- SELINEXOR in Combination w/Bevacizumab and Atezolizumab in Newly Diagnosed Advanced Hepatocellular CarcinomaTerminatedPhase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05093608Written as Selinexor Pill
- A Study of a Fully Human BCMA-targeting CAR (CT103A) Combined With Selinexor in Patients With Relapsed/Refractory Extramedullary Multiple MyelomaStatus unknownPhase 1Chunrui LiNCT05201118Written as Selinexor
- Selinexor Combined With Standard Chemoradiation as Neoadjuvant Treatment in Locally Advanced Rectal CancerStatus unknownPhase 1Sheba Medical CenterNCT02137356Written as dose-escalated selinexor treatment
As the comparator · 4 — what is tested is compared with selinexor
- A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003RecruitingPhase 3Innovent Biologics (Suzhou) Co. Ltd.NCT07623798Written as Selinexor Tablets
- Clinical Study of TQB2934 Injection in Relapsed/Refractory Multiple MyelomaNot yet recruitingPhase 3Chia Tai Tianqing Pharmaceutical Group Co., Ltd.NCT07569757Written as Selinexor tablets
- A Phase III Clinical Study of Purinostat Mesylate for Injection in Patients With Diffuse Large B-cell LymphomaRecruitingPhase 3Chengdu Zenitar Biomedical Technology Co., LtdNCT07011056Written as Selinexor Tablets
- Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line TherapyTerminatedPhase 3Universitätsklinikum Hamburg-EppendorfNCT05675319Written as selinexor/bortezomib/dexamethasone (SVD)
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Selinexor and Pacritinib in JAK Inhibitor-naïve MF Patients With CytopeniasOct 27, 2026NCT07447817
Codes
What other systems call selinexor · ClinicalTrials.gg INT006398
- MeSH (NLM) C585161selinexorConfirmed ClinicalTrials.gov, NLM, Wikidata
- UNII (FDA) 31TZ62FO8FSELINEXORConfirmed FDA, NLM, Wikidata
- RxNorm 2178390One source FDA
- Wikidata Q27256082selinexorConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C102546SelinexorOne source FDA
- DrugBank DB11942One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C585161 | selinexor | Confirmed ClinicalTrials.gov, NLM, Wikidata |
| UNII (FDA) | 31TZ62FO8F | SELINEXOR | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2178390 | — | One source FDA |
| Wikidata | Q27256082 | selinexor | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C102546 | Selinexor | One source FDA |
| DrugBank | DB11942 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.